Look back at pharma news in week to February 22

24 February 2019

By Barbara Obstoj-Cardwell. Editor

Last week’s important research news included positive trial results from Pfizer and Eli Lilly with their tanezumab in chronic low back pain, and from Intercept Pharma for its non-alcoholic steatohepatitis (NASH) candidate Ocaliva. On the deal-making front, attracting attention was Johnson & Johnson unit Janssen’s agreement to access Morphic Therapeutic's expertise on integrin therapeutics. Meantime, the US Food and Drug Administration and its technology unit went on the defensive regarding the quality of generic medicines coming to market.

Tanezumab backs up pain data at a higher dose

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK